Review paper
CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
Abstract
Cell-cycle abnormalities are common in estrogen receptor- and/or progesterone receptor-positive, and HER2-non-overexpressing (HR+/HER2-) breast cancer, and have long been considered potential therapeutic targets. Cyclin-dependent kinase (CDK) 4/6 inhibitors have dramatically changed the therapeutic management of HR+/HER2-advanced breast cancer by prolonging progression-free and overall survival when given in combination with endocrine therapy....
Paper Details
Title
CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
Published Date
Feb 1, 2021
Journal
Volume
55
Pages
75 - 78
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History